EGFR-TKIs耐药继发MET基因扩增肺鳞癌1例报告并文献复习
EGFR-TKIs耐药继发MET基因扩增肺鳞癌1例报告并文献复习
About this item
Full title
Author / Creator
LIU, Yalan , CHEN, Peng and LIU, Xinfu
Publisher
No. 154 Anshan Road, Heping District, Tianjin, PRC, 300052: Editorial board of Chinese Journal of Lung Cancer
Journal title
Language
English
Formats
Publication information
Publisher
No. 154 Anshan Road, Heping District, Tianjin, PRC, 300052: Editorial board of Chinese Journal of Lung Cancer
Subjects
More information
Scope and Contents
Contents
肺腺癌患者目前已常规开展表皮生长因子受体（epidermal growth factor receptor, EGFR）的基因检测，而部分小样本的不吸烟的女性肺鳞癌患者也有EGFR突变的可能，肺癌靶向治疗的快速发展为这一类患者增加了靶向治疗的机会。然而肺鳞癌患者行靶向治疗期间出现耐药是影响后续治疗的重要因素。靶向治疗获得性耐药有多种机制，间充质细胞上皮转化因子（mesenchymal-epithelial transition factor, MET）信号通路的改变是其中常见的耐药机制之一。目前，一些MET的选择性酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）已获批用于伴 MET基因14外显子跳跃突变的非小细胞肺癌，如谷美替尼、塞沃替尼、特泊替尼、卡马替...
Alternative Titles
Full title
EGFR-TKIs耐药继发MET基因扩增肺鳞癌1例报告并文献复习
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11732385
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11732385
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2024.106.32
